Health and Healthcare
Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)
Published:
Last Updated:
This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month. The following companies which are presenting data:
- Allos Therapeutics, Inc. (NASDAQ: ALTH)
- Amgen (NASDAQ: AMGN)
- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
- Array BioPharma, Inc. (NASDAQ: ARRY)
- AstraZeneca’s (NYSE: AZN) Medimmune unit
- Biogen Idec Inc. (NASDAQ: BIIB)
- Celgene Corporation (NASDAQ: CELG)
- Curis, Inc. (NASDAQ: CRIS)
- Immunomedics, Inc. (Nasdaq: IMMU)
- ImmunoGen, Inc. (Nasdaq: IMGN)
- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
- Medarex, Inc. (Nasdaq: MEDX)
- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
- Oncolytics Biotech, Inc. (NASDAQ: ONCY)
- Pfizer (NYSE: PFE)
- Pharmacyclics, Inc. (NASDAQ: PCYC)
- SuperGen Inc. (NASDAQ:SUPG)
- Telik, Inc. (Nasdaq: TELK)
- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)
You can see a full summary of the data being presented at BioHealthInvestor.com site. There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.
JON C. OGG
Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
